Mereo Biopharma Group Plc MREO 深 滬
交易中 09-08 11:18:17 美东时间
1.775
+0.005
+0.28%
華盛通- 最 高1.80
- 今 開1.79
- 成交量 17.77万股
- 最 低 1.7513
- 昨 收 1.77
- 總市值 2.82亿
- 52周最高 4.72
- 市盈率 靜 --
- 換手率 0.11%
- 52周最低 1.47
- 委 比 28.56%
- 總股本 1.59亿
- 歷史最高 17.62
- 量 比 0.79
- 振 幅 2.75%
- 歷史最低 0.301
- 每 手 1
- 風險率 0.89%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多JP Morgan Maintains Overweight on Mereo BioPharma Group, Raises Price Target to $8
JP Morgan analyst Priyanka Grover maintains Mereo BioPharma Group (NASDAQ:MREO) with a Overweight and raises the price target from $7 to $8.
08-25 22:14
Mereo BioPharma signs licensing deal with privately held āshibio
Mereo BioPharma (NASDAQ:MREO) signed an exclusive licensing deal with privately held biotech āshibio, for the antibody therapy vantictumab, intended to treat autosomal dominant osteopetrosis type 2. A...
08-19 21:43
Analysts Offer Insights on Healthcare Companies: TScan Therapeutics (TCRX), Mereo Biopharma Group Plc (MREO) and Oruka Therapeutics (ORKA)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
08-15 18:20
Mereo BioPharma Group Q2 EPS $(0.02) Misses $(0.01) Estimate, Sales $500.000K
Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $(0.01) by 100 percent. This is unchanged from the same period last year. The company
08-12 19:38
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
Mereo BioPharma reported a net loss of $14.6 million for Q2 2025, driven by increased R&D expenses and foreign currency losses, though GA expenses decreased. The company held $56.1 million in cash as of June 30, 2025, supporting operations into 2027. Key highlights include progressing Phase 3 studies for setrusumab in osteogenesis imperfecta, with final data expected by year-end, and advancing alvelestat for AATD-lung disease toward Phase 3 initi...
08-12 11:35
Marex Group plc issues statement regarding NINGI Research report
LONDON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Marex Group plc has rejected a malicious report published by NINGI Research, a short selling fund, accusing it of manipulating Marex's share price for profit. Marex states the report contains inaccuracies and misleading allegations and emphasizes its commitment to integrity, regulatory compliance, and international reporting standards. The company will release its Q2 results on August 13. Marex provides e...
08-05 16:47
Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks
HC Wainwright initiates Ultragenyx at Buy with $80 target, citing strong rare disease pipeline and late-stage data expected by year-end.
07-29 01:16
Mereo BioPharma’s Setrusumab Study Update: Implications for Investors
Mereo BioPharma (LSE) (($GB:MPH)), Mereo Biopharma (($MREO)) announced an updat...
07-24 00:21
Why Is AbbVie Stock Trading Higher On Thursday?
AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase clinical data.
07-11 02:36
Mereo BioPharma’s Phase 3 Study Progresses Smoothly
An announcement from Mereo Biopharma Group Plc ( ($MREO) ) is now available. On...
07-10 19:18
